LLM-Supported Pain Neuroscience Education for Physiotherapy Students
NCT07924319, Not applicable, Completed, İsmail Palalı
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | LLM-Supported Pain Neuroscience Education for Physiotherapy Students | ClinicalTrials.gov |
| NCT number | NCT07924319 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, actual | ClinicalTrials.gov |
| Lead sponsor | İsmail Palalı | ClinicalTrials.gov |
| Conditions | Pain, Chronic Pain, Health Professions Education | ClinicalTrials.gov |
| Interventions | LLM-supported pain neuroscience education, Expert-feedback pain neuroscience education | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Pain Explanation Competence (PEC) on an unseen cross-context transfer scenario. | 12 weeks after completion of the 4-week intervention | Study-specific analytic rubric with six domains (scientific accuracy; clarity/comprehensibility; alignment with contemporary pain science/biopsychosocial framework; misconception correction; safe, non-nocebogenic communication; patient/context adaptation), each scored 1-5. Total 6-30; higher = better. Mean of three blinded assessors. | ClinicalTrials.gov |
| Secondary | Pain Explanation Competence (PEC) across all assessment scenarios | Baseline, immediately after the 4-week intervention, and 12 weeks after intervention completion | Mean total PEC score across the three written fictional clinical scenarios completed at each time point, scored with the study-specific analytic rubric (six domains, each 1-5; total range 6-30; higher scores indicate greater competence). Each response was independently scored by three allocation-blinded assessors and the mean rating was used. Analysed with a linear mixed-effects model (group, time, group×time). | ClinicalTrials.gov |
| Secondary | PEC domain scores on the transfer scenario | 12 weeks after intervention completion | Separate scores for each of the six PEC domains (scientific accuracy; clarity and patient comprehensibility; alignment with contemporary pain science and the biopsychosocial framework; identification and correction of misconceptions; safe, non-threatening and non-nocebogenic communication; patient/context adaptation) on the unseen cross-context transfer scenario. Each domain is scored 1-5; higher scores indicate better performance. Holm correction applied across the six domains. | ClinicalTrials.gov |
| Secondary | Metaphor competence | Baseline and 12 weeks after intervention completion | Quality of metaphor or analogy use in written pain explanations, scored 1-5 according to scientific appropriateness, conceptual correspondence, clarity, potential for misunderstanding, and adaptation to the patient context. Higher scores indicate more effective metaphor use. Scored by three allocation-blinded assessors; compared between groups adjusted for baseline. | ClinicalTrials.gov |
| Secondary | Proportion of unsafe pain explanations | 12 weeks after intervention completion | Proportion of responses containing at least one predefined potentially unsafe communication element (scientifically false or misleading mechanisms; equating pain intensity with tissue damage; fragility- or danger-promoting language; fear-provoking statements about movement or loading; unsupported absolute reassurance; invalidating or judgmental language; potentially harmful recommendations). Classified by three allocation-blinded assessors; analysed with a binomial generalized estimating equation clustered by participant. | ClinicalTrials.gov |
| Secondary | Pain neurophysiology knowledge (Revised Neurophysiology of Pain Questionnaire-Turkish, RNPQ-TR) | Baseline, immediately after the 4-week intervention, and 12 weeks after intervention completion | Turkish version of the Revised Neurophysiology of Pain Questionnaire (13 items; total score 0-13). Higher scores indicate greater pain-neurophysiology knowledge. | ClinicalTrials.gov |
| Secondary | Pain knowledge and attitudes (Knowledge and Attitudes of Pain Questionnaire-Turkish, KNAP-TR) | Baseline, immediately after the 4-week intervention, and 12 weeks after intervention completion | Turkish version of the Knowledge and Attitudes of Pain Questionnaire, assessing contemporary musculoskeletal pain knowledge and attitudes in healthcare students. Higher scores indicate greater alignment with contemporary pain science. | ClinicalTrials.gov |
| Other | External generative-AI use (contamination) | Immediately after the 4-week intervention and 12 weeks after intervention completion | Self-reported independent use of generative AI outside supervised sessions for pain-science learning, creating pain explanations or metaphors, practising clinical scenarios, or receiving AI-generated feedback (yes/no). Reported as the proportion of participants in each group and examined in sensitivity analyses of the primary outcome. | ClinicalTrials.gov |
| Other | Intervention fidelity | During the 4-week intervention (weekly sessions) | Proportion of participants completing each component of the scenario-based practice sequence (attendance, independent initial response, feedback phase, critical appraisal, independent revision, adaptation task) in each weekly session, together with actual session duration. In the LLM-supported group, completion of the standardized LLM interaction and any protocol or technical deviations were also recorded. Used to define the per-protocol sensitivity population (at least 75% intervention completion). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)